AltMountain

Ally Bridge Group (NY) LLC

New York, NY · CRD 291072
Hedge fund manager

Ally Bridge Group (NY) LLC is an SEC-registered investment adviser based in New York, NY that reports managing 3 hedge funds on Form ADV. It reports $218.9 million in regulatory assets under management. Its private funds, of all types, hold $340.7 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +27.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +69.7% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$218.9 millionForm ADV Item 5.F
Gross assets of private funds
$340.7 millionAll private fund types, Form ADV
Hedge funds managed
33 private funds in total
Employees
7Form ADV Item 5.A
Registration
SEC-registered adviserCRD 291072
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+27.7%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+69.7%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$77.6 million23 positions, 2026-06-30
$91$130$170Q3 2024Q1 2025Q3 2025Q1 202613F est. $170S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+17.9%+14.8%
Q1 2026+8.2%-4.6%
Q4 2025+1.6%+2.4%
Q3 2025+31.5%+7.8%
Q2 2025+9.6%+10.4%
Q1 2025-3.0%-4.5%
Q4 2024-8.2%+2.1%
Q3 2024+2.0%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 14 share positions ($43,411,958) reported by Ally Bridge Group (NY) LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Edgewise Therapeutics Inc17.34%
  • Promis Neurosciences Inc15.50%
  • Minerva Neurosciences Inc12.78%
  • Amylyx Pharmaceuticals Inc12.20%
  • Shattuck Labs Inc9.82%
  • Obsidian Therapeutics Inc9.57%
  • An2 Therapeutics Inc6.45%
  • Eupraxia Pharmaceuticals Inc4.84%
  • Avalo Therapeutics Inc4.75%
  • Inventiva SA1.93%
StockValue% of 13F portfolioSharesShares vs prior quarter
Edgewise Therapeutics Inc$7,528,45817.34%185,430+122.61%
Promis Neurosciences Inc$6,730,46115.50%620,319Unchanged
Minerva Neurosciences Inc$5,545,92512.78%1,655,500-23.91%
Amylyx Pharmaceuticals Inc$5,296,20012.20%182,000New
Shattuck Labs Inc$4,263,7969.82%625,190New
Obsidian Therapeutics Inc$4,152,6259.57%302,449New
An2 Therapeutics Inc$2,799,9966.45%526,315Unchanged
Eupraxia Pharmaceuticals Inc$2,103,2104.84%231,122-8.35%
Avalo Therapeutics Inc$2,060,7974.75%134,429-10.38%
Inventiva SA$838,5531.93%227,250-64.20%
Vogenx Inc$745,2561.72%32,701New
Traws Pharma Inc$466,8671.08%786,236Unchanged
Perspective Therapeutics Inc$449,9941.04%163,634-78.00%
Assembly Biosciences Inc$429,8200.99%18,298-86.93%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 4 new positions, 13 sold out, 1 increased, 6 reduced and 3 unchanged.

Number of positions (a count, not dollars)

  • New positions4
  • Increased1
  • Unchanged3
  • Reduced6
  • Sold out13

New positions

StockValueShares
Amylyx Pharmaceuticals Inc$5,296,200182,000
Shattuck Labs Inc$4,263,796625,190
Obsidian Therapeutics Inc$4,152,625302,449
Vogenx Inc$745,25632,701

Sold out

StockValue at Jun 30, 2026Shares held then
First Tracks Biotherapeutics$5,719,854284,287
Axsome Therapeutics Inc.$4,036,99216,493
Whitehawk Therapeutics Inc$3,746,161817,939
Climb Bio Inc$3,249,203249,172
Kura Oncology Inc$3,181,300290,000
Cytomx Therapeutics Inc.$2,906,250775,000
Palisade Bio Inc$2,568,6101,229,000
Solid Biosciences Inc$2,557,030255,959
Urogen Pharma LTD$2,545,93469,183
Ideaya Biosciences Inc$2,515,72567,500
Alumis Inc$2,151,55676,459
Ovid Therapeutics Inc$1,680,069624,561
Ibio Inc$682,757390,147

Largest increases

StockChange in sharesChangeValue nowShares now
Edgewise Therapeutics Inc+102,130+122.61%$7,528,458185,430

Largest reductions

StockChange in sharesChangeValue nowShares now
Assembly Biosciences Inc-121,702-86.93%$429,82018,298
Minerva Neurosciences Inc-520,302-23.91%$5,545,9251,655,500
Perspective Therapeutics Inc-580,324-78.00%$449,994163,634
Inventiva SA-407,550-64.20%$838,553227,250
Avalo Therapeutics Inc-15,571-10.38%$2,060,797134,429
Eupraxia Pharmaceuticals Inc-21,053-8.35%$2,103,210231,122

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (3)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.

Fund vehicles: feeder funds and single-deal vehicles (2)

Fund
Gross assets
Minimum
Owners
Adviser
Ally Bridge Medalpha International Fund Limited
Cayman IslandsHedge fund
Gross assets$107M
Minimum$5.0M
Owners21
AdviserAlly Bridge Group (NY) LLC
Ally Bridge Medalpha US Fund L.P.
Delaware, United StatesHedge fund
Gross assets$2.0M
Minimum$5.0M
Owners9
AdviserAlly Bridge Group (NY) LLC

Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠